Piper Sandler raised the firm’s price target on Vertex Pharmaceuticals to $400 from $390 and keeps an Overweight rating on the shares after a solid Q3 print and FY23 CF product revenue guidance raised. Combining this with upside from other income and lower than expected tax expense, Vertex delivered a solid non-GAAP EPS beat, the firm adds. Piper continues to view Vertex as a core large cap holding.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $380 from $370 at Cantor Fitzgerald
- Vertex Pharmaceuticals price target raised to $415 from $389 at BMO Capital
- Vertex Pharmaceuticals price target lowered to $347 from $350 at RBC Capital
- Vertex Pharmaceuticals price target raised to $408 from $399 at Barclays
- Vertex Pharmaceuticals price target raised to $390 from $380 at H.C. Wainwright